JL, Amarin announced (August 7, 2020) that it is supporting a large trial of Vascepa in treating patients afflicted with COVID-19; P-I is Kaiser-Permanente. JT and CG have elaborated on that topic by noting AMRN is supporting 3 randomized, blinded trials of Vascepa in ~ 3500 patients in the United States, Canada and Argentina. See Amarin’s earnings call, 11/05/2020.
Reasons correspond to those you advance.